KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $171.7 million.

  • Alnylam Pharmaceuticals' Net Cash Flow rose 24729.23% to $171.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $655.2 million, marking a year-over-year increase of 28768.75%. This contributed to the annual value of $655.2 million for FY2025, which is 28768.75% up from last year.
  • According to the latest figures from Q4 2025, Alnylam Pharmaceuticals' Net Cash Flow is $171.7 million, which was up 24729.23% from $377.9 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' Net Cash Flow's 5-year high stood at $495.6 million during Q3 2022, with a 5-year trough of -$283.7 million in Q1 2022.
  • In the last 5 years, Alnylam Pharmaceuticals' Net Cash Flow had a median value of $44.9 million in 2022 and averaged $57.5 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Net Cash Flow tumbled by 870126.54% in 2021, and later soared by 212442.5% in 2024.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Net Cash Flow stood at -$271.3 million in 2021, then grew by 23.15% to -$208.5 million in 2022, then decreased by 10.92% to -$231.2 million in 2023, then surged by 49.58% to -$116.6 million in 2024, then soared by 247.29% to $171.7 million in 2025.
  • Its Net Cash Flow stands at $171.7 million for Q4 2025, versus $377.9 million for Q3 2025 and $66.1 million for Q2 2025.